| Periodicals Home | Search | User Pref |
Help | Logout |
| AJKD Home | Table
of Contents |
All Issues | Order | About this Journal |
<< Issue |
>> Issue |
![]() |
Kamyar Kalantar-Zadeh, MD, MPH*Sections
|
|
| Abstract | TOP |
Protein-energy malnutrition (PEM) and inflammation are common and usually concurrent in maintenance dialysis patients. Many factors that appear to lead to these 2 conditions overlap, as do assessment tools and such criteria for detecting them as hypoalbuminemia. Both these conditions are related to poor dialysis outcome. Low appetite and a hypercatabolic state are among common features. PEM in dialysis patients has been suggested to be secondary to inflammation; however, the evidence is not conclusive, and an equicausal status or even opposite causal direction is possible. Hence, malnutrition-inflammation complex syndrome (MICS) is an appropriate term. Possible causes of MICS include comorbid illnesses, oxidative and carbonyl stress, nutrient loss through dialysis, anorexia and low nutrient intake, uremic toxins, decreased clearance of inflammatory cytokines, volume overload, and dialysis-related factors. MICS is believed to be the main cause of erythropoietin hyporesponsiveness, high rate of cardiovascular atherosclerotic disease, decreased quality of life, and increased mortality and hospitalization in dialysis patients. Because MICS leads to a low body mass index, hypocholesterolemia, hypocreatininemia, and hypohomocysteinemia, a “reverse epidemiology” of cardiovascular risks can occur in dialysis patients. Therefore, obesity, hypercholesterolemia, and increased blood levels of creatinine and homocysteine appear to be protective and paradoxically associated with a better outcome. There is no consensus about how to determine the degree of severity of MICS or how to manage it. Several diagnostic tools and treatment modalities are discussed. Successful management of MICS may ameliorate the cardiovascular epidemic and poor outcome in dialysis patients. Clinical trials focusing on MICS and its possible causes and consequences are urgently required to improve poor clinical outcome in dialysis patients.
| (Click on a term to search this journal for other articles containing that term.) |
| Protein-energy malnutrition | TOP |
| Inadequate nutrient intake |
| Anorexia* |
| Uremic toxicity |
| Impaired gastric emptying |
| Inflammation
with/without comorbid conditions* |
| Emotional and/or psychological disorders |
| Dietary restrictions |
| Prescribed restrictions: low-potassium low-phosphate regimens |
| Social constraints: poverty, inadequate dietary support |
| Physical incapacity: inability to acquire or prepare food or to eat |
| Nutrient losses during dialysis |
| Loss through hemodialysis membrane into hemodialysate |
| Adherence to hemodialysis membrane or tubing |
| Loss into peritoneal dialysate |
| Hypercatabolism caused by comorbid illnesses |
| Cardiovascular
diseases* |
| Diabetic complications |
| Infection and/or
sepsis* |
| Other comorbid
conditions* |
| Hypercatabolism associated with dialysis treatment |
| Negative protein balance |
| Negative energy balance |
| Endocrine disorders of uremia |
| Resistance to insulin |
| Resistance to growth hormone and/or IGF-1 |
| Increased serum level of or sensitivity to glucagons |
| Hyperparathyroidism |
| Other endocrine disorders |
| Acidemia with metabolic acidosis |
| Concurrent nutrient loss with frequent blood losses |
*The given factor may also be associated with inflammation. |
| Fig 1. Mean levels of
biochemical measures of nutritional status as a function of glomerular
filtration rate (GFR) in the Modification of Diet in Renal Disease Study.
Estimated mean levels with 95% confidence limits of biochemical
nutritional markers are shown as a function of GFR (males, solid line;
females, dashed line) controlling for age, race, and use of protein- and
energy-restricted diets. In men, the slope of the relationship was greater
at a GFR of 12 mL/min/1.73 m2 than 55 mL/min/1.73 m2
for serum total cholesterol (P = 0.014). (A) Males, N = 1,065
(P = 0.004); females, N = 698 (P < 0.001); (B) males, N =
1,065 (P < 0.001); females, N = 698 (P < 0.001); (C)
males, N = 1,063 (P = 0.052); females, N = 694 (P = 0.63);
(D) males, N = 1,017 (P < 0.001); females, N = 664 (P
< 0.001). To convert albumin in g/dL to g/L, multiply by 10;
transferrin in mg/dL to g/L, multiply by 0.01; cholesterol in mg/dL to
mmol/L, multiply by 0.02586. Used with permission from Kidney
International, vol 57, pages 1688–1703, 2000.36 |
|
|
|
Composite indices that include a combination of assessment measures within
these categories also are used, such as the Subjective Global Assessment of
Nutrition (SGA)38,39
or Malnutrition-Inflammation Score (MIS).23
More technologically based nutritional measures that have been used in dialysis
patients include dual-energy X-ray absorptiometry,40,41
total-body nitrogen or potassium measurements,42–44
underwater weighing,45
bioelectrical impedance analysis,41
and near-infrared interactance.46,47
The 4 categories of nutritional assessment tools are listed in Table 2
and have been reviewed in detail elsewhere.18,48
As shown in Table 2
, many of these nutritional assessment tools also detect
the presence of inflammation and measure its severity.
| Nutritional intake |
| Direct: diet recalls
and diaries, food-frequency questionnaires* |
| Indirect: based on urea
nitrogen appearance: nPNA (nPCR)* |
| Body composition |
| Weight-based measures:
BMI, weight for height, edema-free fat-free weight* |
| Skin and muscle
anthropometry by caliper: skinfolds, extremity muscle mass* |
| Total-body elements: total-body potassium |
| Energy-beam-based
methods: DEXA, BIA, NIR* |
| Other energy-beam-related methods: total-body nitrogen |
| Other methods: underwater weighing |
| Scoring systems |
| Conventional SGA and
its modifications (eg, Dialysis Malnutrition Score,159 MIS,
Canada-USA-version)* |
| Other scores:
Hemodialysis Prognostic Nutritional Index, others (eg, Wolfson et
al,55
Merkus et al,188
Merckman et al,154
Harty et al190)* |
| Laboratory values |
| Visceral proteins
(negative acute-phase reactants): albumin, prealbumin, transferrin* |
| Lipids: cholesterol,
triglycerides, other lipids and lipoproteins* |
| Somatic proteins and nitrogen surrogates: creatinine, serum urea nitrogen |
| Growth factors: IGF-1, leptin |
| Peripheral-blood cell count: lymphocyte count |
Abbreviations: nPNA, normalized protein nitrogen appearance; nPCR, normalized protein catabolic rate, DEXA, dual-energy X-ray absoptiometry; BIA, bioelectrical impedance analysis, NIR, near-infra red interactance. Data from Kalantar-Zadeh and Kopple.18,48 |
*The given tool may also detect inflammation. |
| Inflammation | TOP |
| Causes of inflammation from CKD or decreased glomerular filtration rate |
| Decreased clearance of proinflammatory cytokines |
| Volume overload* |
| Oxidative stress (eg,
oxygen radicals)* |
| Carbonyl stress (eg, pentosidine and advanced glycation end products) |
| Decreased levels of
antioxidants (eg, vitamin E, vitamin C, carotenoids, selenium,
glutathione)* |
| Deteriorating
protein-energy nutritional state and food intake* |
| Coexistence of comorbid conditions |
| Inflammatory diseases with kidney involvement (eg, systemic lupus erythematosus; AIDS) |
| Increased prevalence of
comorbid conditions (eg, cardiovascular disease; diabetes mellitus;
advanced age)* |
| Additional inflammatory factors related to dialysis treatment |
| Hemodialysis: |
| Exposure to dialysis tubing |
| Dialysis membranes with decreased biocompatibility (eg, cuprophane) |
| Impurities in dialysis water and/or dialysate |
| Backfiltration or backdiffusion of contaminants |
| Foreign bodies (such as polytetonfluoroethylene) in dialysis access grafts |
| Intravenous catheter |
| Peritoneal dialysis: |
| Episodes of overt or
latent peritonitis* |
| Pcritoneal dialysis catheter as a foreign body and its related infections |
| Constant exposure to peritoneal dialysis solution |
*The given factor may also be associated with PEM. |
| Positive Acute-Phase Reactants | Negative Acute-Phase Reactants |
| Proinflammatory cytokines | Nutritional markers |
| IL-6 | Albumin |
TNF- (cachechtin) |
Transferrin or TIBC |
Other interleukins
(IL-1 , etc) |
Prealbumin (transthyretin) |
| Other positive acute-phase reactants | Cholesterol |
| CRP | Leptin* |
| Serum amyloid A | Other negative acute-phase reactants |
| Ferritin | Histidine-rich glycoprotein |
Fibrinogen, 1-antitrgpsin T,
haptoglobin |
|
*A recent report has questioned the role of leptin as an acute-phase protein.189 | |
| Relationship between malnutrition and inflammation | TOP |
(TNF-
), not only promote catabolic
processes, engendering both protein degradation and suppression of protein
synthesis, but also induce anorexia.95–97
Low appetite has been associated with increased levels of inflammatory markers
in hemodialysis patients.49
from monocytes.108
Thus, PEM may decrease host resistance and predispose to latent or overt
infection, which is an inflammatory disorder.
| Fig 2. Schematic
representation of the causes and consequences of MICS. Abbreviation: DM,
diabetes mellitus. |
|
|
|
| Refractory anemia | TOP |
.118,119
We recently reported that the logarithm of serum IL-6 level had the strongest
correlation with required EPO dose in 339 hemodialysis patients, and the
association remained statistically significant in different statistical analyses
and after multivariate adjustments.120
Both serum CRP and TNF-
levels also
showed a similar trend, and their associations with EPO dose remained
significant in some, but not all, analysis modalities we conducted in this
study.120
have been shown to
inhibit EPO production in vitro.130
Furthermore, increased release or activation of such inflammatory cytokines as
IL-6 or TNF-
has been shown to have
a suppressive effect on erythropoiesis.131
IL-6 and IL-1 have been found to antagonize the ability of EPO to stimulate bone
marrow proliferation in culture.132
Moreover, patients with inflammation may be more prone to gastrointestinal
bleeding.125,126
Finally, it is important to mention that use of intravenous iron for anemia
treatment in dialysis patients per se may lead to oxidative stress,
inflammation, and consequent atherosclerosis, as indicated by Drueke et
al.133
| Atherosclerotic cardiovascular disease | TOP |
| Poor clinical outcome and reverse epidemiology | TOP |
| Diagnosis and management of MICS | TOP |